Finance

Lists
Q2 2027 earnings • released • Revenue beat +1.47%
See results
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥3,665.00
-5.30%
(-205.00) 1D
Nov 6, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
Â¥3,805
High
Â¥3,830
Low
Â¥3,665
Mkt. cap
170.58B
Avg. vol.
89.54K
Volume
122.40K
Dividend
3.27%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
13.58
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥3,805
High
Â¥3,830
Low
Â¥3,665
Mkt. cap
170.58B
Avg. vol.
89.54K
Volume
122.40K
Dividend
3.27%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
13.58
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 4, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
22.11B / 21.79B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
26.80B
24.77B
23.39B
22.11B
Cost of goods sold
14.50B
13.95B
11.96B
11.84B
Cost of revenue
14.50B
13.95B
11.96B
11.84B
Research and development expenses
-
22.52B
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.15B
-15.41B
10.34B
9.68B
Operating expense
9.15B
10.07B
10.34B
9.68B
Total operating expenses
23.65B
24.02B
22.29B
21.52B
Operating income
3.16B
756.00M
1.10B
599.00M
Other non operating income
10.00M
-10.00M
10.00M
-78.00M
EBT including unusual items
4.20B
3.28B
6.29B
376.00M
EBT excluding unusual items
3.52B
948.00M
1.82B
661.00M
Income tax expense
915.00M
482.00M
1.53B
-122.00M
Effective tax rate
21.81%
14.68%
24.32%
-32.45%
Other operating expenses
-
129.00M
-
-
Net income
3.23B
2.76B
4.72B
468.00M
Net profit margin
12.05%
11.16%
20.19%
2.12%
Earnings per share
-
-
-
-
Interest and investment income
614.00M
224.00M
729.00M
193.00M
Interest expense
-7.00M
-8.00M
-8.00M
-11.00M
Net interest expenses
607.00M
216.00M
721.00M
182.00M
Depreciation and amortization charges
-
2.83B
-
-
EBITDA
4.31B
1.92B
2.26B
1.76B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps